Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.~* Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.~* The subject has a radiographically measurable tumor.~* The subject is able to carry out daily life activities without difficulty.~* The subject is able to swallow and retain oral medication.~* The subject does not have significant side effects from previous anti-cancer treatment.~* The subject has adequate organ and blood cell counts.~* Sexually active subjects must use medically acceptable methods of contraception during the course of the study.~Exclusion Criteria:~* The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.~* The subject has a brain tumor.~* Current severe, uncontrolled systemic disease.~* History of clinically significant heart, lung, or eye/vision problems.~* The subject has high blood pressure that is not well-controlled with medication.~* The subject has a permanent pacemaker.~* The subject is pregnant or breastfeeding.~* Positive for Hepatitis B, Hepatitis C, or HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Trametinib plus Docetaxel
- Treatment Group 2 (Type: EXPERIMENTAL): Trametinib plus Erlotinib
- Treatment Group 3 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed
- Treatment Group 4 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed and Carboplatin
- Treatment Group 5 (Type: EXPERIMENTAL): Trametinib plus nab-Paclitaxel
- Treatment Group 6 (Type: EXPERIMENTAL): Trametinib plus Pemetrexed and Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).